Hager Biosciences, LLC is a preclinical-stage drug discovery organization practicing innovative discovery medicinal chemistry. Hager's main mission is to become a preferred partner to pharmaceutical and biotech firms by providing therapeutic leads through out-licensing for unmet medical needs. Central to the business model is Hager's capability to design and synthesize proprietary small fragment molecules for modular adaptation into new or existing drug candidate optimization or novelization projects. Hager's discovery FragPhore ® platform provides a competitive and efficient advantage for rapid novel lead generation, optimization and drug rescue via profile/properties improvement, as well as modular fragments swap for intellectual property enhancement. Hager’s highly cost-effective and efficient discovery research process including using outsourced network infrastructures has a solid track records of innovative preclinical pharmaceutical candidate discovery in CNS therapeutic spaces attested by several IP estates generated. Recent examples of awarded patents as well as filed patent applications include: 11,505,555 10,329,301 11,414,425 10,815,242 11,142,529 11,312,721 16/445,854 63/399,509 WO2020247447 WO2020247445 US2022/0259224 63/403,019 63/400,894